Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

ur Phase II trial testing bavituximab and docetaxel in advanced breast cancer patients. Our anti-viral program received global attention with a publication in the leading journal Nature Medicine highlighting the broad anti-viral potential of bavituximab and other anti-PS antibodies, and we were also awarded a broad U.S. patent covering anti-viral applications of antibodies that directly target PS. These developments, following a major government contract award last quarter to study bavituximab in viral hemorrhagic fever infections, have established our PS-targeting anti-viral platform as an approach that could represent a completely new class of drugs for the treatment of life-threatening viral infections. We look forward to reporting continued progress in our anti-PS programs in the coming months, as well as providing an update on progress in our Cotara(R) clinical program."

Mr. King continued, "Our Avid manufacturing subsidiary continued to expand its client base during the quarter and increased its manufacturing capacity with the addition of an innovative single-use bioreactor system, which should allow Avid to meet the growing demand for its cell culture production services using state-of-the-art, cost-effective technology. Avid revenues recorded this quarter were lower than last year's as a result of the timing of shipments of finished product to customers, but based on product now being readied for shipping and our backlog of orders in hand, we expect robust revenue growth from Avid over the remainder of the fiscal year, with revenues in the third quarter of FY 2009 estimated at upwards of $5 million."

Mr. King concluded, "Despite the turmoil in the global financial markets, we have never been more optimistic about the potential of our lead drug candidates. The encouraging progress in our clinical programs to date and increasing scientific recognition of the promise of our innovative technology have already
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... some patients is real and is only natural. However, ... in Cancer , the incidence and effects of ... computed tomography (CT) lung cancer screening exams are far ... , "Unsubstantiated claims of systemic and harmful patient ... continue to delay implementation of CT lung cancer screening ...
(Date:7/25/2014)... Ross A. Clevens, MD, FACS, and ... join the exclusive Obagi Clinical Advisory Board, comprised of ... plastic surgeons and dermatologists. , Dr. Clevens recently ... of thought leaders held its first meeting in three ... give Obagi the opportunity to meet with eight of ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
(Date:7/25/2014)... HealthDay Reporter , THURSDAY, July ... girls and boys are getting the human papillomavirus (HPV) vaccine, ... officials said Thursday. The U.S. Centers for Disease Control ... 12 get the three-dose vaccine so that protection is in ... Yet, despite a slight increase over the year before, only ...
Breaking Medicine News(10 mins):Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Too Few Teens Receive HPV Shot, CDC Says 2Health News:Too Few Teens Receive HPV Shot, CDC Says 3
... George Dahlman, senior vice president of public policy for ... the U.S. Senate Subcommittee on Defense Appropriations, calling for ... at the Department of Defense (DoD). , , ... blood cancers, including chronic lymphocytic leukemia (CLL), lymphoma and ...
... ... DIA Meeting in San Diego, Calif. , ... Boston, Mass. (PRWEB) June 18, 2009 -- CenterWatch , ... annual surveys aimed at better understanding physician referrals to clinical trials and study volunteer ...
... healthcare alliance Innovation Celebration , , ANAHEIM, Calif., June ... medical devices SpA, Italy, yesterday introduced a new innovation in ... fit in the palm of a hand, can record a ... the thumbs. , , The ecg@home(TM) debuted at ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... effect on relationships and lead to significant changes in how ... and emotional level, according a study in the June issue ... from Northern Ireland have come up with four key recommendations ... nine males and seven females, aged between 33 and 78. ...
... - 2009 rankings include 10 specialties and Honor Roll - ... Group today released its second annual rankings by specialty of ... and featured in the August issue of ... July 21. , , The 2009 America,s Best ...
Cached Medicine News:Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2Health News:HealthFrontier Introduces New Innovation in Web-Based Remote Health Monitoring Technology 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 3Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 4Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 2Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 3
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... March 12 Genta,Incorporated (Nasdaq: GNTA ) today announced ... 31, 2007. The Company noted,significant recent milestones, including:, ... biomarker initiates in melanoma -- New oral product, ... 505(b)(2) strategy -- Tesetaxel, a leading ...
... Achieve Weight Loss with Education & ... ... Findings in the Journal of,the American Medical Association on the largest ... prevention.,The combination of both personal contact and web-based support are,identified as ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10Study Finds Personal and Web-Based Support Equal Weight Loss Success 2Study Finds Personal and Web-Based Support Equal Weight Loss Success 3Study Finds Personal and Web-Based Support Equal Weight Loss Success 4
... ophthalmic solution is an anti-infective ... doctor may instruct you to ... eye infection caused by bacteria. ... are the 2 types of ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: